Prospective Observational Study On The Impact Of Nebilet In Blood Pressure Control In Hypertensive Patients (HYIMPACT)
NCT ID: NCT06938516
Last Updated: 2025-04-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
4537 participants
OBSERVATIONAL
2023-12-20
2029-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A total of approximately 5,000 hypertensive patients with or without cardiovascular comorbidities will be enrolled across seven Asian countries (Malaysia, Indonesia, the Philippines, Korea, Vietnam, Thailand, and Taiwan). Patients newly initiated on Nebilet®-based treatment or already receiving Nebilet® for no more than two weeks prior to screening will be eligible for inclusion.
Patients will be followed at regular intervals for up to three years. The study will also assess the correlation between home and office blood pressure measurements and compare Nebilet® monotherapy with combination therapy in achieving target blood pressure control. The findings from this study will provide real-world insights into the clinical management of hypertension with Nebilet® and its impact on patient outcomes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study of Efficacy and Safety of Nebivolol in Korean Patients With Essential Hypertension
NCT03847350
Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)
NCT01415531
Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients
NCT00734630
Effect of Different Antihypertensive Drugs on Central Blood Pressure
NCT05328310
A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy
NCT00785512
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The HYIMPACT study is a multinational, multicenter, observational, longitudinal study designed to evaluate the real-world effectiveness, safety, and adherence of Nebilet® (nebivolol) in hypertensive patients across seven Asian countries. This study will provide insights into the clinical utility of Nebilet® in achieving sustained blood pressure control over time, while also assessing the influence of cardiovascular risk factors on treatment outcomes. By systematically collecting data from patients in routine clinical settings, HYIMPACT aims to bridge the gap between controlled clinical trials and real-world practice, offering valuable evidence to optimize hypertension management strategies.
Study Objectives. HYIMPACT aims to assess the impact of Nebilet®-based treatment on systolic and diastolic blood pressure control from baseline to 12, 24, and 36 months. The study will determine the proportion of patients achieving target blood pressure levels (\<140/90 mmHg) and evaluate adherence using the Morisky 8-Item Medication Adherence Scale (MMAS). Additionally, the study will compare the effectiveness of Nebilet® monotherapy versus combination therapy in achieving blood pressure control. Patient-reported outcomes will be analyzed using the SF-36 and MINICHAL questionnaires, providing insights into the impact of treatment on quality of life. The study will also assess the correlation between home and office blood pressure measurements and investigate the association between Nebilet® use and major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and cardiovascular mortality.
Study Design and Population. HYIMPACT is an observational, prospective, longitudinal study enrolling approximately 5,000 hypertensive patients across Malaysia, Indonesia, the Philippines, Korea, Vietnam, Thailand, and Taiwan. Eligible patients will be adults aged 18 years or older with newly diagnosed or uncontrolled hypertension, defined as an office systolic blood pressure of at least 140 mmHg and/or diastolic blood pressure of at least 90 mmHg at screening. Patients may be included if they have either been newly prescribed Nebilet® or have been on Nebilet®-based treatment for no more than two weeks prior to enrollment. Individuals with recent major cardiovascular events within the last three months, severe heart failure classified as NYHA Class IV, or contraindications to Nebilet® as per the Summary of Product Characteristics will be excluded. The study will involve 300 to 500 physicians, ensuring representation across a wide range of real-world clinical settings.
Variables to be Collected. The study will systematically collect patient demographic and clinical data, including medical history, cardiovascular risk factors such as diabetes, obesity, and hypercholesterolemia, and medication use. Blood pressure measurements will be recorded at baseline and at each follow-up visit, with additional data collected on prescription patterns, dose adjustments, and patient adherence. Laboratory parameters, including lipid profiles, glycated hemoglobin (HbA1c), and renal function markers, will be documented when available. Cardiovascular outcomes such as MACE, including myocardial infarction, stroke, and cardiovascular mortality, will be monitored throughout the study.
Follow-Up and Data Collection. Patients will be evaluated at baseline and followed up at 12, 24, and 36 months. Blood pressure will be measured at each visit using standardized protocols, and home blood pressure readings will be encouraged to assess their correlation with office measurements. Patient-reported quality of life and adherence assessments will be conducted using validated questionnaires. Any adverse events, including treatment-emergent and serious adverse events, will be documented. Data will be recorded in an electronic case report form (eCRF) using the CLINYTICS platform, ensuring consistency and standardization across study sites.
Quality Control Measures. To ensure high data quality, the study will implement standardized definitions and data collection procedures across all sites. Investigators will receive training on study protocols, and automated validation checks within the eCRF system will help identify inconsistencies. Regular site audits will be conducted to monitor compliance, and periodic investigator meetings will be held to review study progress. Ethics committee approvals will be obtained in each participating country, and all data will be handled in compliance with Good Clinical Practice (GCP) guidelines and local data protection regulations.
Statistical Analysis. Continuous variables such as blood pressure values will be summarized as means with standard deviations, while categorical variables will be presented as frequencies and percentages. Changes in systolic and diastolic blood pressure over time will be analyzed using paired t-tests and repeated measures ANOVA, with non-parametric alternatives applied when normality assumptions are not met. The effectiveness of Nebilet® monotherapy versus combination therapy will be assessed using logistic regression for categorical outcomes and ANOVA for continuous variables. Cox proportional hazards models will evaluate the association between Nebilet® treatment and cardiovascular outcomes. Pearson correlation coefficients will be used to analyze the relationship between home and office blood pressure measurements, and structural equation modelling (SEM) will be applied to address potential regression dilution bias.
Study Governance and Data Ownership. HYIMPACT is an investigator-led study with data collection coordinated through a centralized electronic data management system. Each participating physician retains ownership of individual patient data, while consolidated and anonymized study results will be used for scientific analysis and publication. Patient confidentiality will be strictly maintained through secure data storage, anonymization, and regulatory compliance with local data protection laws.
The findings from HYIMPACT will provide valuable insights into the long-term real-world effectiveness of Nebilet® in managing hypertension. By analyzing treatment adherence, quality of life, and cardiovascular outcomes over time, this study will contribute to optimizing hypertension treatment strategies and improving patient care across diverse healthcare settings.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hypertensive patients - with or without cardiovascular comorbidities (such as coronary artery disease, heart failure, peripheral artery disease, cerebrovascular disease, arrhythmias, and valvular heart disease) - who are newly prescribed or are already on Nebilet based treatment (no more than for 2 weeks at screening).
* Hypertensive patients willing to provide consent to participate in the study.
* Women of reproductive age who are willing to use adequate means of contraception.
Exclusion Criteria
* Patient with heart failure based on New York Heart Association (NYHA) Functional Classification- Class IV.
* Patients with contraindications to Nebilet based treatment as per respective Summary of Product Characteristic (SmPC) which in the treating physician's judgment may jeopardize the subject by his or her participation in this study or may hamper his or her ability to perform and complete procedures required in the study.
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
A.Menarini Asia-Pacific Holdings Pte Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr Radhika Mehta
Role: STUDY_DIRECTOR
A. Menarini Asia-Pacific Holding Pte Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Telogorejo Hospital
Semarang, Central Java, Indonesia
Bethesda Hospital
Yogyakarta, Central Java, Indonesia
Panti rapih Hospital
Yogyakarta, Central Java, Indonesia
Husada Utama Hospital
Surabaya, East Java, Indonesia
Premere Surabaya Hospital
Surabaya, East Java, Indonesia
National Cardiovascular Center Harapan Kita Hospital
Jakarta, Jakarta Special Capital Region, Indonesia
Metropolitan Medical Centre Hospital
Jakarta, Jakarta Special Capital Region, Indonesia
Bidakara Medical Centre
Selatan, Jakarta Special Capital Region, Indonesia
PT Ekamas International Hospital
Pekanbaru, Riau, Indonesia
Stella Maris Hospital
Makassar, South Sulawasi, Indonesia
Bukit Asam Medika Hospital
Palembang, South Sumatra, Indonesia
Advent Hospital
Bandung, West Java, Indonesia
Borromeus Hospital
Bandung, West Java, Indonesia
RSUD Syamsudin Hospital
Sukabumi, West Java, Indonesia
Semen Padang Hospital
Padang, West Sumatra, Indonesia
DrThong,Leow,Chiam & Partners
Kuala Lumpur, Kuala Lumpur, Malaysia
Klinik Pembangunan Sdn. Bhd
Kuala Lumpur, Kuala Lumpur, Malaysia
Pantai HKL
Kuala Lumpur, Kuala Lumpur, Malaysia
Columbia Asia Hospital Seremban
Seremban, Negeri Sembilan, Malaysia
Mawar Medical Centre
Seremban, Negeri Sembilan, Malaysia
Bukit Tinggi Medical Centre
Klang, Selangor, Malaysia
Mary Mediatrix Medical Center
Lipa, Batangas, Philippines
Veterans Memorial Medical Center
Quezon City, Manila, Philippines
Kangbuk Samsung Hospital
Seoul, Jongno District Seoul, South Korea
Eunpyeong St. Mary's Hospital
Seoul, Seoul, South Korea
Chonnam National University Hospital
Gwangju, , South Korea
Far Eastern Memorial Hospital (FEMH)
New Taipei City, Banqiao, Taiwan
Changhua Christian Hospital (CCH)
Changhua, Changhua County, Taiwan
Chang Gung Memorial Hospital-Chiayi branch (CGMH-CY)
Pozi, Chiayi County, Taiwan
Chung Gung Memorial Hospital-Linkou Branch (CGMH-LK)
Taoyuan District, Guishan District, Taiwan
Hualien Tzu-Chi Hospital (HTCH)
Hualien City, Hualien County, Taiwan
Asia University Hospital (AUH)
Taipei, Nangang Dist., Taiwan
National Cheng Kung University Hospital (NCKUH)
Tainan City, North District, Taiwan
Kaohsiung Medical University Hospital (KMUH)
Kaohsiung City, Sanmin District, Taiwan
Taipei Medical University Hospital (TMUH)
Taipei, Xinyi District, Taiwan
Taichung Veterans General Hospital (TVGH)
Taichung, Xitun District, Taiwan
Chi-Mei Medical Center (CMC)
Tainan City, Yongkang Dist., Taiwan
MacKay Memorial Hospital (MMH)
Taipei, Zhongshan District, Taiwan
National Taiwan University Hospital (NTUH)
Taipei, Zhongzheng District, Taiwan
Vajira Hospital Namindradhiraj University
Dusit, Bangkok, Thailand
Wetchakarunrasm Hospital
Nong Chok, Bangkok, Thailand
Burapha University
Chon Buri, Changwat Chon Buri, Thailand
Central Chet Institute
Nonthaburi, Changwat Nonthaburi, Thailand
Chiang Mai University
Chiang Mai, Chiang Mai, Thailand
Anand Mahidhol Hospital
Lopburi, Lopaburi, Thailand
CanTho General Hospital
Can Tho, Can Tho City, Vietnam
Hanoi Heart Hospital
Hanoi, Hanoi, Vietnam
Cho Ray Hospital
Ho Chi Minh City, Ho Chi Minh, Vietnam
Hue Central Hospital
Huế, Hue, Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AMAP/22/NebHyp/001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.